MedTrace Logo

Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

NCT04323189 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-01-16

No results posted yet for this study

Summary

This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to during placebo and compared to matched controls.

Conditions

Interventions

DRUG

Sitagliptin 100mg

Sitagliptin will be administered daily for 7 days, with a study day on day 7.

DRUG

Placebo Oral Tablet

Placebo will be administered daily for 7 days, with a study day on day 7.

Sponsors & Collaborators

Principal Investigators

  • Jessica R Wilson, MD, MS · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-26
Primary Completion
2025-02-27
Completion
2026-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04323189 on ClinicalTrials.gov